Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Kamoun WS, et al. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5. Nat Biomed Eng. 2019. PMID: 30952988
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Kamoun W, et al. Pharmaceutics. 2020 Oct 20;12(10):996. doi: 10.3390/pharmaceutics12100996. Pharmaceutics. 2020. PMID: 33092175 Free PMC article.
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC. Dumont N, et al. Among authors: kamoun ws. Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14. Nanomedicine. 2019. PMID: 30654182
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Sequist LV, et al. Among authors: kamoun ws. Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11. Oncologist. 2019. PMID: 30975923 Free PMC article. Clinical Trial.
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK. Kodack DP, et al. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27. doi: 10.1073/pnas.1216078109. Epub 2012 Oct 15. Proc Natl Acad Sci U S A. 2012. PMID: 23071298 Free PMC article.
37 results